1. Indications and Usage
\nAcute Ischemic Stroke:
\nTreatment of mild to moderate acute thrombotic cerebral infarction .
\nNote: It is specifically indicated for ischemic stroke and is contraindicated in hemorrhagic stroke.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Intravenous (IV) Infusion ONLY.
\nRecommended Dosage:
\nStandard Dose: 0.15 PNA Units per time.
\nFrequency: Once daily.
\nDuration: A typical course of treatment is 3 weeks .
\nCritical Administration Instructions:
\nTiming: Therapy should be initiated within 48 hours of symptom onset .
\nReconstitution: Dissolve one vial (0.15 PNA Units) in 50 mL or 100 mL of 0.9% Sodium Chloride Injection .
\nInfusion Time: Administer over 30 minutes.
\nSpeed Control: Infusion speed must not be too fast. The first 15 minutes should be administered slowly to monitor for hypotension .
\n3. Mechanism of Action
\nKallikrein-Kinin System Activation:
\nUrinary kallidinogenase is a proteolytic enzyme that converts endogenous high-molecular-weight kininogen into kinin and kallidin .
\nMicrovascular Dilatation:
\nThese kinins act on vascular smooth muscle to cause vasodilation, particularly in the microvasculature.
\nCerebral Protection:
\nIt increases cerebral blood flow, improves microcirculation, inhibits platelet aggregation, and enhances oxygen delivery to ischemic brain tissue .
\n4. Safety and Warnings
\nHypotension:
\nThe most significant risk is a sudden and severe drop in blood pressure.
\nAction: Monitor blood pressure closely. If significant hypotension occurs, discontinue immediately and administer pressor agents .
\nContraindications:
\nHemorrhagic Stroke: Contraindicated in the acute phase of cerebral hemorrhage or other hemorrhagic diseases .
\nAllergy: Patients with a history of drug allergy or allergic constitution should use with caution .
\nDrug Interactions (Critical):
\nACE Inhibitors: Concomitant use with Angiotensin-Converting Enzyme (ACEI) inhibitors (e.g., Captopril, Lisinopril) is contraindicated as they have a synergistic hypotensive effect, potentially leading to dangerous hypotension .
\n5.Adverse Reactions and Clinical Research
\nMost Common Adverse Reactions:
\nVomiting, facial flushing and heat sensation, headache, diarrhea, conjunctival congestion, palpitations, and injection site redness\/itching .
\nClinical Research Highlights:
\nClinical trials indicate it improves neurological function and quality of life in acute ischemic stroke patients when used within 48 hours .
\n6.Drug Interactions
\nAntihypertensives:
\nMay enhance the hypotensive effect of antihypertensive agents.
\nSpecific Warning: Strictly avoid combining with ACEI class drugs due to the risk of syncope or shock .
\n7.Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Urinary Kallidinogenase (a glycoprotein of 238 amino acids) .
\nAppearance: White lyophilized solid or powder.
\nPackaging: Single-use vial (0.15 PNA Units).
\nStorage: Sealed and stored at controlled room temperature.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u51ef\u529b\u5eb7\u00ae\uff08Kailikang\u00ae\uff09
\nGeneric Name: Urinary Kallidinogenase
\nStrength: 0.15 PNA unit per vial
\nManufacturer: Techpool Bio-Pharma Co., Ltd.
\nMarketing Authorization Holder: Techpool Bio-Pharma Co., Ltd.
\nApproval Date in China: 2005
\nRegistration Number: \u56fd\u836f\u51c6\u5b57H20052065
\nStorage: Store in a sealed container, keep in cool, dry place protected from moisture. Refer to the full package insert for detailed storage specifications.<\/p>\n
Price&Cost:Contact Us now for the best price of Urinary Kallidinogenase \uff08Kailikang\uff09<\/p>\n","protected":false},"featured_media":4380,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[25,73],"product_tag":[],"class_list":["post-4379","product","type-product","status-publish","has-post-thumbnail","product_cat-injection","product_cat-chinese-innovative-drug","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n